Ribavirin in chronic hepatitis C: past and future

被引：1
作者：
Loustaud-Ratti, Veronique [1 ]
Rousseau, Annick [2 ]
Marquet, Pierre [2 ]
Denis, Francois [3 ]
Alain, Sophie [3 ]
机构：
[1] CHU Limoges, Dept Internal Med, Limoges, France
[2] Univ Limoges, CHU Limoges, INSERM, U850, F-87065 Limoges, France
[3] Univ Limoges, CHU Limoges, Dept Virol, Avenir Inserm,EA3175, F-87065 Limoges, France
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2009年 / 7卷 / 03期
关键词：
SUSTAINED VIROLOGICAL RESPONSE; ALPHA-2A PLUS RIBAVIRIN; COMBINATION THERAPY; PEGYLATED INTERFERON; VIRUS-INFECTION; GENOTYPE-1; PATIENTS; EPOETIN-ALPHA; COINFECTED PATIENTS; ANTIVIRAL ACTIVITY; DOUBLE-BLIND;
D O I：
10.1586/ERI.09.5
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：249 / 253
页数：5
相关论文
共 46 条
  • [1] Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study
    Afdhal, NH
    Dieterich, DT
    Pockros, PJ
    Schiff, ER
    Shiffman, ML
    Sulkowski, MS
    Wright, T
    Younossi, Z
    Goon, BL
    Tang, KL
    Bowers, PJ
    [J]. GASTROENTEROLOGY, 2004, 126 (05) : 1302 - 1311
  • [2] Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C
    Arase, Y
    Ikeda, K
    Tsubota, A
    Suzuki, F
    Suzuki, Y
    Saitoh, S
    Kobayashi, M
    Akuta, N
    Someya, T
    Hosaka, T
    Sezaki, H
    Kobayashi, M
    Kumada, H
    [J]. INTERVIROLOGY, 2005, 48 (2-3) : 138 - 144
  • [3] Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C
    Asahina, Y
    Izumi, N
    Enomoto, N
    Uchihara, M
    Kurosaki, M
    Onuki, Y
    Nishimura, Y
    Ueda, K
    Tsuchiya, K
    Nakanishi, H
    Kitamura, T
    Miyake, S
    [J]. JOURNAL OF HEPATOLOGY, 2005, 43 (04) : 623 - 629
  • [4] Ribavirin: Analytical determinations since the origin until today
    Bosch, M. Espinosa
    Sanchez, A. J. Ruiz
    Rojas, F. Sanchez
    Ojeda, C. Bosch
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 45 (02) : 185 - 193
  • [5] PILOT-STUDY OF COMBINATION THERAPY WITH RIBAVIRIN PLUS INTERFERON-ALFA FOR INTERFERON ALFA-RESISTANT CHRONIC HEPATITIS-C
    BRILLANTI, S
    GARSON, J
    FOLI, M
    WHITBY, K
    DEAVILLE, R
    MASCI, C
    MIGLIOLI, M
    BARBARA, L
    [J]. GASTROENTEROLOGY, 1994, 107 (03) : 812 - 817
  • [6] Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin
    Bronowicki, Jean-Pierre
    Ouzan, Denis
    Asselah, Tarik
    Desmorat, Herve
    Zarski, Jean-Pierre
    Foucher, Juliette
    Bourliere, Marc
    Renou, Christophe
    Tran, Albert
    Melin, Pascal
    Hezode, Christophe
    Chevalier, Michelle
    Bouvier-Alias, Magali
    Chevaliez, Stephane
    Montestruc, Francois
    Lonjon-Domanec, Isabelle
    Pawlotsky, Jean-Michel
    [J]. GASTROENTEROLOGY, 2006, 131 (04) : 1040 - 1048
  • [7] Dosage of ribavirin in patients with Hepatitis C should be based on renal function:: A population pharmacokinetic analysis
    Bruchfeld, A
    Lindahl, K
    Schvarcz, R
    Ståhle, L
    [J]. THERAPEUTIC DRUG MONITORING, 2002, 24 (06) : 701 - 708
  • [8] Analysis of ribavirin mutagenicity in human hepatitis C virus infection
    Chevaliez, Stephane
    Brillet, Rozenn
    Lazaro, Ester
    Hezode, Christophe
    Pawlotsky, Jean-Michel
    [J]. JOURNAL OF VIROLOGY, 2007, 81 (14) : 7732 - 7741
  • [9] Ribavirin concentration at week four is an independend predictor for sustained virological response after treatment of hepatitis C genotype 2/3 (NORDynamic trial)
    Christensen, P. B.
    Alsio, A. A.
    Buhl, M. R.
    Farkkila, M.
    Morch, K.
    Sangfelt, P.
    Lagging, M.
    Norkrans, G.
    Pedersen, C.
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 : S6 - S7
  • [10] Crespo M, 2007, ANTIVIR THER, V12, P1217
12345